Anti-inflammatory effect of AMPK signaling pathway in rat model of diabetic neuropathy

Inflammopharmacology

Volumn 24, Issue 5, 2016, Pages 207-219

  Hasanvand, Amin ^a   Amini khoei, Hossein ^b,c   Hadian, Mohammad Reza ^d   Abdollahi, Alireza ^e   Tavangar, Seyed Mohammad ^f   Dehpour, Ahmad Reza ^a,c   Semiei, Elika ^a   Mehr, Shahram Ejtemaei ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

AMPK; Cytokines; Diabetic neuropathy; Inflammatory response; MNCV; Rat

Indexed keywords

ADENYLATE KINASE; C REACTIVE PROTEIN; DORSOMORPHIN; GLUCOSE; INTERLEUKIN 6; METFORMIN; TUMOR NECROSIS FACTOR; ANTIDIABETIC AGENT; AUTACOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; MALE; MOTOR NERVE CONDUCTION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPROTECTION; NONHUMAN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SCIATIC NERVE; SCIATIC NERVE INJURY; SIGNAL TRANSDUCTION; SPINAL GANGLION; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; WISTAR RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; MALE; METFORMIN; RANDOM ALLOCATION; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84981276428     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-016-0275-2     Document Type: Article

References (47)

1. Akbar DH (2003) Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine 20:215–218. doi:10.1385/endo:20:3:215
2. Bordet T et al (2008) Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy. J Pharmacol Exp Ther 326:623–632. doi:10.1124/jpet.108.139410
3. Boyer JS, Morgan MM, Craft RM (1998) Microinjection of morphine into the rostral ventromedial medulla produces greater antinociception in male compared to female rats. Brain Res 796:315–318. doi:10.1016/S0006-8993(98)00353-9
4. Brummett CM, Padda AK, Amodeo FS, Welch KB, Lydic R (2009) Perineural dexmedetomidine added to ropivacaine causes a dose-dependent increase in the duration of thermal antinociception in sciatic nerve block in rat. Anesthesiology 111:1111–1119. doi:10.1097/ALN.0b013e3181bbcc26
5. Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ (2006) Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes 55:819–825. doi:10.2337/diabetes.55.03.06.db05-0934
6. Cho K et al (2015) Antihyperglycemic mechanism of metformin occurs via the AMPK/LXR [agr]/POMC pathway. Sci Rep 5:8145. doi:10.1038/srep08145
7. Correia S et al (2008) Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. Med Chem [Shariqah (United Arab Emirates)] 4:358–364. doi:10.2174/157340608784872299
8. Coste T, Gerbi A, Vague P, Maixent J, Pieroni G, Raccah D (2004) Peripheral diabetic neuropathy and polyunsaturated fatty acid supplementations: natural sources or biotechnological needs? Cell Mol Biol (Noisy-le-Grand, France) 50:845–853. doi:10.1070/T578
9. Eslami A, Lujan J (2010) Western blotting: sample preparation to detection. J Vis Exp JoVE. doi:10.3791/2359
10. Fillingim RB, Maixner W (1995) Gender differences in the responses to noxious stimuli. Pain Forum 4:209–221. doi:10.1016/S1082-3174(11)80022-X
11. Foretz M et al (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Investig 120:2355–2369. doi:10.1172/jci40671
12. Gaskin FS, Kamada K, Yusof M, Korthuis RJ (2007) 5′-AMP-activated protein kinase activation prevents postischemic leukocyte-endothelial cell adhesive interactions. Am J Physiol Heart Circ Physiol 292:H326–H332. doi:10.1152/ajpheart.00744.2006
13. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA (2005) PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28:2093–2099. doi:10.2337/diacare.28.9.2093
14. Gonzalez-Clemente JM et al (2005) Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clin Endocrinol 63:525–529. doi:10.1111/j.1365-2265.2005.02376.x
15. Hasegawa T et al (2006) Amelioration of diabetic peripheral neuropathy by implantation of hematopoietic mononuclear cells in streptozotocin-induced diabetic rats. Exp Neurol 199:274–280. doi:10.1016/j.expneurol.2005.11.001
16. Hills CE, Brunskill NJ (2009) Cellular and physiological effects of C-peptide. Clin Sci (London, England: 1979) 116:565–574. doi:10.1042/cs20080441
17. Ido Y, Carling D, Ruderman N (2002) Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 51:159–167. doi:10.2337/diabetes.51.1.159
18. Jin HY, Liu WJ, Park JH, Baek HS, Park TS (2009) Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 40:536–544. doi:10.1016/j.arcmed.2009.09.005
19. Kimura T, Kato E, Machikawa T, Kimura S, Katayama S, Kawabata J (2014) Hydroxylamine enhances glucose uptake in C2C12 skeletal muscle cells through the activation of insulin receptor substrate 1. Biochem Biophys Res Commun 445:6–9. doi:10.1016/j.bbrc.2014.01.039
20. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403. doi:10.1056/NEJMoa012512
21. Lee MJ et al (2007) A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Ren Physiol 292:F617–F627. doi:10.1152/ajprenal.00278.2006
22. Leinninger GM, Edwards JL, Lipshaw MJ, Feldman EL (2006) Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nat Clin Pract Neurol 2:620–628. doi:10.1038/ncpneuro0320
23. Liu X, Chhipa RR, Nakano I, Dasgupta B (2014) The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther 13:596–605. doi:10.1158/1535-7163.mct-13-0579
24. Ma J, Liu J, Yu H, Chen Y, Wang Q, Xiang L (2015) Beneficial effect of metformin on nerve regeneration and functional recovery after sciatic nerve crush injury in diabetic rats. Neurochem Res 1–8. doi:10.1007/s11064-015-1803-y
25. McGee SL, van Denderen BJ, Howlett KF, Mollica J, Schertzer JD, Kemp BE, Hargreaves M (2008) AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5. Diabetes 57:860–867. doi:10.2337/db07-0843
26. Novikova DS, Garabadzhiu AV, Melino G, Barlev NA, Tribulovich VG (2015) AMP-activated protein kinase: structure, function, and role in pathological processes. Biochem Biokhimiia 80:127–144. doi:10.1134/s0006297915020017
27. Roy Chowdhury SK et al (2012) Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes. Brain J Neurol 135:1751–1766. doi:10.1093/brain/aws097
28. Saeedi Saravi SS, Hasanvand A, Shahkarami K, Dehpour AR (2016) The protective potential of metformin against acetaminophen-induced hepatotoxicity in BALB/C mice. Pharm Biol 1–8. doi:10.1080/13880209.2016.1185633
29. Steinberg GR et al (2006) Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 4:465–474. doi:10.1016/j.cmet.2006.11.005
30. Takeuchi M, Takino J, Yamagishi S (2010) Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. Curr Drug Targets 11:1468–1482. doi:10.2174/1389450111009011468
31. Tracy JA, Dyck PJB (2008) The spectrum of diabetic neuropathies physical medicine and rehabilitation clinics of North America 19:1–26. doi:10.1016/j.pmr.2007.10.010
32. Uceyler N, Rogausch JP, Toyka KV, Sommer C (2007) Differential expression of cytokines in painful and painless neuropathies. Neurology 69:42–49. doi:10.1212/01.wnl.0000265062.92340.a5
33. Ullah I, Ullah N, Naseer MI, Lee HY, Kim MO (2012) Neuroprotection with metformin and thymoquinone against ethanol-induced apoptotic neurodegeneration in prenatal rat cortical neurons. BMC Neurosci 13:11. doi:10.1186/1471-2202-13-11
34. Valk GD, Kriegsman DM, Assendelft WJ (2002) Patient education for preventing diabetic foot ulceration a systematic review. Endocrinol Metab Clin N Am 31:633–658. doi:10.1016/S0889-8529(02)00021-X
35. Vinik AI, Kong X, Megerian JT, Gozani SN (2006) Diabetic nerve conduction abnormalities in the primary care setting. Diabetes Technol Ther 8:654–662. doi:10.1089/dia.2006.8.654
36. Wada R, Yagihashi S (2005) Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 1043:598–604. doi:10.1196/annals.1338.067
37. Wang MY, Unger RH (2005) Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone. Am J Physiol Endocrinol Metab 288:E216–E221. doi:10.1152/ajpendo.00004.2004
38. Wang S, Xu J, Song P, Viollet B, Zou MH (2009) In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I. Diabetes 58:1893–1901. doi:10.2337/db09-0267
39. Wiesenfeld-Hallin Z (2005) Sex differences in pain perception. Gend Med 2:137–145. doi:10.1016/S1550-8579(05)80042-7
40. Wu Y, Song P, Xu J, Zhang M, Zou M-H (2007) Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 282:9777–9788. doi:10.1074/jbc.M608310200
41. Yorek MA et al (1993) Reduced motor nerve conduction velocity and Na (+)-K(+)-ATPase activity in rats maintained on L-fucose diet. Reversal by myo-inositol supplementation. Diabetes 42:1401–1406. doi:10.2337/diab.42.10.1401
42. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Philadelphia, Pa) 1:369–375. doi:10.1158/1940-6207.capr-08-0081
43. Zangiabadi N, Ahrari MN, Nakhaee N (2007) The effect of omega-3 fatty acids on nerve conduction velocity (NCV) and F-wave latency in patients with diabetic polyneuropathy. Am J Pharmacol Toxicol 2:1–3. doi:10.3844/ajptsp.2007.1.3
44. Zhang H, Zhang H, Dougherty PM (2013) Dynamic effects of TNF-alpha on synaptic transmission in mice over time following sciatic nerve chronic constriction injury. J Neurophysiol 110:1663–1671. doi:10.1152/jn.01088.2012
45. Zhou G et al (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Investig 108:1167–1174. doi:10.1172/jci13505
46. Zhuo XZ et al (2013) Isoproterenol instigates cardiomyocyte apoptosis and heart failure via AMPK inactivation-mediated endoplasmic reticulum stress. Apoptosis Int J Program Cell Death 18:800–810. doi:10.1007/s10495-013-0843-5
47. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109–110. doi:10.1016/0304-3959(83)90201-4